Author

Arūnas Girčys

Observed names: A. Gircys, Arunas Gircys

Institution: Swissmedic

Observed institution: Swissmedic

ORCID: 0009-0003-6417-3066

Observed ORCID: 0009-0003-6417-3066

OpenAlex ID: A5011835309

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

2021 · Abigail L. Koch, Paz J. Vellanki, et al. · Clinical Cancer Research · 68

A decade comparison of regulatory decision patterns for oncology products to all other non‐oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration

2023 · Ulrich‐P. Rohr, Mario Iovino, et al. · Clinical and Translational Science · 19

Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective

2023 · Matea Pavic, Anita Wolfer, et al. · Journal of Clinical Oncology · 9

Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001–2020): A Meta-Analysis of Pivotal Randomised Controlled Trials

2026 · Parisa Rahimzadeh, Qiyu Li, et al. · The Lancet Regional Health - Europe · 1

Trends in pivotal clinical trial design and biomarker use: a retrospective analysis of oncology drug approval in Switzerland from 2001 to 2020

2025 · Parisa Rahimzadeh, Qiyu Li, et al. · BMJ Connections Oncology · 1

Decision-Making at Swissmedic, the Swiss Regulatory Agency, with a Focus on (Neo)adjuvant Cancer Treatments

2024 · Matea Zosso-Pavic, Qiyu Li, et al. · Oncology

Data from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

2023 · Abigail L. Koch, Paz J. Vellanki, et al.

Data from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

2023 · Abigail L. Koch, Paz J. Vellanki, et al.

Supplementary Table S1 from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

2023 · Abigail L. Koch, Paz J. Vellanki, et al.

1349P A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products between Swissmedic, EMA and FDA

2022 · U-P. Rohr, M. Iovino, et al. · Annals of Oncology

Works count: 10

Citation count: 98

H-index: 3

I10-index: 2